174 related articles for article (PubMed ID: 25581761)
1. Emerging biomarkers in the detection and prognosis of prostate cancer.
Filella X; Foj L
Clin Chem Lab Med; 2015 Jun; 53(7):963-73. PubMed ID: 25581761
[TBL] [Abstract][Full Text] [Related]
2. A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer.
Song J; Ma S; Sokoll LJ; Eguez RV; Höti N; Zhang H; Mohr P; Dua R; Patil D; May KD; Williams S; Arnold R; Sanda MG; Chan DW; Zhang Z
Theranostics; 2021; 11(13):6214-6224. PubMed ID: 33995654
[No Abstract] [Full Text] [Related]
3. Detection and Prognosis of Prostate Cancer Using Blood-Based Biomarkers.
Jin W; Fei X; Wang X; Song Y; Chen F
Mediators Inflamm; 2020; 2020():8730608. PubMed ID: 32454797
[TBL] [Abstract][Full Text] [Related]
4. Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer.
Saoud R; Heidar NA; Cimadamore A; Paner GP
Cells; 2020 Sep; 9(9):. PubMed ID: 32957584
[TBL] [Abstract][Full Text] [Related]
5. Upcycling HOXB13: enhancing prostate cancer detection with a novel antibody
Augspach A; Rubin MA
J Pathol; 2024 Apr; 262(4):391-394. PubMed ID: 38332742
[TBL] [Abstract][Full Text] [Related]
6. Relapsing disease.
Murphy GP; Mahler C; Ho RC; Krane RJ; Pontes JE
Cancer; 1992 Jul; 70(1 Suppl):368. PubMed ID: 1376208
[No Abstract] [Full Text] [Related]
7. Prostate cancer screening: Unacceptable in the under 50s.
Braillon A; Dubois G
BMJ; 2007 Dec; 335(7632):1225. PubMed ID: 18079521
[No Abstract] [Full Text] [Related]
8. Editorial: Prostate Cancer: What We Know and What We Would Like to Know.
Taverna G; Cote RJ; Grizzi F
Front Oncol; 2015; 5():114. PubMed ID: 26052506
[No Abstract] [Full Text] [Related]
9. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
Filella X; Foj L
Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27792187
[TBL] [Abstract][Full Text] [Related]
10. Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate Cancer.
Kim JH; Hong SK
Biomed Res Int; 2015; 2015():475920. PubMed ID: 26339615
[TBL] [Abstract][Full Text] [Related]
11. Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.
Birnbaum JK; Feng Z; Gulati R; Fan J; Lotan Y; Wei JT; Etzioni R
Cancer Epidemiol Biomarkers Prev; 2015 Apr; 24(4):677-82. PubMed ID: 25613117
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for evaluation of prostate cancer prognosis.
Esfahani M; Ataei N; Panjehpour M
Asian Pac J Cancer Prev; 2015; 16(7):2601-11. PubMed ID: 25854335
[TBL] [Abstract][Full Text] [Related]
13. Novel biomarkers and advanced imaging modalities in the early detection of prostate cancer.
Parsons JK
J Urol; 2015 Apr; 193(4):1084-5. PubMed ID: 25596362
[No Abstract] [Full Text] [Related]
14. Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine.
Ferro M; Lucarelli G; Bruzzese D; Perdonà S; Mazzarella C; Perruolo G; Marino A; Cosimato V; Giorgio E; Tagliamonte V; Bottero D; De Cobelli O; Terracciano D
Anticancer Res; 2015 Feb; 35(2):1017-23. PubMed ID: 25667489
[TBL] [Abstract][Full Text] [Related]
15. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.
Siddiqui MM; Rais-Bahrami S; Turkbey B; George AK; Rothwax J; Shakir N; Okoro C; Raskolnikov D; Parnes HL; Linehan WM; Merino MJ; Simon RM; Choyke PL; Wood BJ; Pinto PA
JAMA; 2015 Jan; 313(4):390-7. PubMed ID: 25626035
[TBL] [Abstract][Full Text] [Related]
16. Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing.
Song C; Chen H; Wang T; Zhang W; Ru G; Lang J
Prostate; 2015 Apr; 75(5):500-16. PubMed ID: 25597612
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.
de la Calle C; Patil D; Wei JT; Scherr DS; Sokoll L; Chan DW; Siddiqui J; Mosquera JM; Rubin MA; Sanda MG
J Urol; 2015 Jul; 194(1):65-72. PubMed ID: 25636659
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.
Roberts MJ; Chow CW; Schirra HJ; Richards R; Buck M; Selth LA; Doi SA; Samaratunga H; Perry-Keene J; Payton D; Yaxley J; Lavin MF; Gardiner RA
Prostate; 2015 Apr; 75(5):539-49. PubMed ID: 25597828
[TBL] [Abstract][Full Text] [Related]
19. Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancer.
Léon P; Seisen T; Cussenot O; Drouin SJ; Cattarino S; Compérat E; Renard-Penna R; Mozer P; Bitker MO; Rouprêt M
Urol Oncol; 2015 Sep; 33(9):384.e21-7. PubMed ID: 25595576
[TBL] [Abstract][Full Text] [Related]
20. ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.
Crawford ED; Moul JW
Oncology (Williston Park); 2015 Jan; 29(1):55-8, 65-6. PubMed ID: 25592210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
